|Mr. Seth H. Z. Fischer||Chief Exec. Officer and Director||1.24M||N/A||61|
|Mr. Mark K. Oki CPA||Chief Financial Officer and Chief Accounting Officer||480k||N/A||48|
|Mr. John L. Slebir Esq.||Sr. VP of Bus. Devel., Gen. Counsel and Sec.||667.16k||N/A||52|
|Dr. Santosh T. Varghese M.D.||Chief Medical Officer||564.94k||N/A||47|
|Mr. Richard Fante||Sr. Advisor||N/A||N/A||52|
VIVUS, Inc., a biopharmaceutical company, develops and commercializes therapies to address unmet medical needs in the United States and the European Union. The company offers Qsymia for the treatment of obesity as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index of 30 or greater, or 27 or greater in the presence of at least one weight-related comorbidity, such as hypertension, type 2 diabetes mellitus or high cholesterol; and STENDRA, an oral phosphodiesterase type 5 inhibitor for the treatment of erectile dysfunction. It is also developing Qsymia, which has completed Phase II studies for the treatment of obstructive sleep apnea and diabetes, as well as for other obesity-related diseases, including nonalcoholic steatohepatitis, nonalcoholic fatty liver disease, hyperlipidemia, and hypertension. In addition, the company is developing Tacrolimus, which has completed Phase IIa studies for the treatment of pulmonary arterial hypertension. It has development, license and clinical trial, and commercial supply agreement with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of avanafil, a PDE5 inhibitor compound for the oral and local treatment of male and female sexual dysfunction. The company also has license and commercialization agreements with Berlin-Chemie AG and Auxilium Pharmaceuticals, Inc. to commercialize and promote STENDRA; and with Sanofi Winthrop Industrie to commercialize and promote avanafil. VIVUS, Inc. was founded in 1991 and is headquartered in Campbell, California.
VIVUS, Inc.’s ISS Governance QualityScore as of September 1, 2017 is 9. The pillar scores are Audit: 2; Board: 9; Shareholder Rights: 5; Compensation: 10.